Latest Glucokinase Stories
CHARLOTTESVILLE, Va., Oct. 12 /PRNewswire/ -- Beta-Pro LLC, announced today that it has expanded its operations to accommodate increasing demands from pharmaceutical drug discovery and research institutes in the $2 billion hepatocyte market.
Understanding mechanism underlying SIRT6 activity may help treat diabetes, cancer.
BOULDER, Colo. and THOUSAND OAKS, Calif., Dec. 14 /PRNewswire-FirstCall/ -- Array BioPharma Inc.
Array BioPharma, a biopharmaceutical company, has reported positive preclinical data of a novel small molecule glucokinase activator, ARRY-403, a drug for the treatment of Type 2 diabetes.
Array BioPharma Inc. (Nasdaq: ARRY) today announced the presentation of preclinical data on a novel small molecule glucokinase activator (GKA), ARRY-403, a drug for the treatment of Type 2 diabetes.
Research and Markets (http://www.researchandmarkets.com/research/d99eac/competitor_analysi) has announced the addition of the "Competitor Analysis: Emerging Diabetes Drugs" report to their offering.
In many patients with type 2 diabetes, the liver acts like a sugar factory on overtime, churning out glucose throughout the day, even when blood sugar levels are high. Scientists at the Salk Institute for Biological Studies discovered a key cellular switch that controls glucose production in liver cells.